SAMSUNG-BIOEPIS
27.9.2018 01:02:06 CEST | Business Wire | Press release
Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) under the 351(k) pathway for SB5, a biosimilar candidate referencing HUMIRA® i (adalimumab). The BLA for SB5 was submitted by Samsung Bioepis in July 2018.
The BLA for SB5 was based on data derived from a randomized, double-blind 52-week Phase 3 study, in which 544 patients with moderate to severe rheumatoid arthritis despite methotrexate (MTX) therapy were randomized to receive either SB5 or the adalimumab reference product (ADL). At Week 24, the ACR20 response rate was 72.4% in the SB5 group versus 72.2% in the ADL group. The safety profile of SB5 was comparable to ADL up to Week 24. At Week 24, 254 patients receiving ADL were re-randomized in a 1:1 ratio to continue on ADL or transitioned to SB5, and 254 patients receiving SB5 continued to receive SB5. Up to Week 52, the efficacy, safety and immunogenicity profiles remained comparable between all three treatment groups. There were no treatment emergent issues or clinically relevant immunogenicity precipitated by alternating subjects between treatments.
Outside of the United States, SB5 has so far received regulatory approval from the European Commission, Korea's Ministry of Food and Drug Safety, Australia's Therapeutic Goods Administration and Health Canada.
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that includes six late-stage candidates that cover the therapeutic areas of immunology, oncology and diabetes. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com .
i Humira® is a registered trademark of AbbVie Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180926006096/en/
Contact:
MEDIA CONTACT: Samsung Bioepis Co., Ltd. Mingi Hyun +82-31-8061-1594 mingi.hyun@samsung.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Saudi Maritime & Logistics Congress Highlights Maritime Sector Integration and Opportunities for Trade and Investment Growth in the Kingdom22.10.2026 16:52:00 CEST | Press release
The Saudi Maritime & Logistics Congress highlighted Saudi Arabia’s role in supporting the continuity of trade flows and strengthening supply chain resilience as it opened at Jeddah Superdome, bringing together representatives of government entities, maritime transport and logistics leaders, and the business community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022362613/en/ The Congress takes place as rapid changes in trade and shipping prompt companies to reassess transport routes and operational and investment choices. It provides a platform for dialogue among stakeholders to explore opportunities for cooperation and strengthen integration between ports and maritime, land transport and logistics services, supporting operational efficiency and supply chain reliability. In his opening address, His Excellency Eng. Fawaz Alsahli, President of the Transport General Authority in Saudi Arabia, emphasised that the Kingdom’s
Ministerial Roundtable Discusses Mobilising Green Investments for a Resilient and Inclusive Global Economy22.10.2026 16:49:00 CEST | Press release
HE Saeed Mohammed Al Tayer, Chairman of the World Green Economy Organization, opened the Ministerial Roundtable titled "From Ambition to Bankable Action-Mobilising Green Investments for a Resilient and Inclusive Global Economy," during the 12th World Green Economy Summit (WGES), held on 21-22 October 2026 at the Dubai World Trade Centre under the theme "From Success to Scale: Showcasing the Green Economy." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022803264/en/ Ministerial Roundtable Discusses Mobilising Green Investments for a Resilient and Inclusive Global Economy (Photo: AETOSWire) The session was attended by HE Dr. Amna bint Abdullah Al Dahak, Minister of Climate Change and Environment, the United Arab Emirates; HE Aliou Gori Diouf, Minister of Environment and Ecological Transition, Senegal; HE Balarabe Abbas Lawal, Minister of Environment, Nigeria; HE Steven Victor, Minister of Agriculture, Fisheries, and the En
SBC Medical Initiates Development of a DNA Methylation Test to Estimate Biological Age22.10.2026 15:00:00 CEST | Press release
Leveraging the Waqoo Group’s research and technology ecosystem to establish a new personal baseline for proactive health and longevity SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that it has commenced in-house development of a test designed to estimate an individual’s biological age using DNA methylation analysis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022474590/en/ SBC Medical Initiates Development of a DNA Methylation Test to Estimate Biological Age Development will be led by the Company’s AI and longevity-focused subsidiary, SBC AI Longevity Innovation, Inc. The initiative will leverage the regenerative medicine research and technology base established by Waqoo, Inc. (TOKYO: 4937), a consolidated subsidiary of SBC Medical, and its subsidiary Cel
Lenovo Expands AI Library with Proven, Validated Use Cases to Accelerate Business Outcomes and Drive Greater Value Per Token22.10.2026 15:00:00 CEST | Press release
New enterprise AI use cases and research findings show how organizations can move from AI experimentation to measurable value up to 24x faster1 while improving the economics of AISignal65 analysis shows how enterprise customers can lower cost per token by up to 70% at full utilization with on-premises Lenovo Hybrid AI Factories compared to hyperscale API pricing4 Lenovo today expanded the Lenovo AI Library with new, validated AI use cases, extending its portfolio of enterprise-ready solutions that can help organizations move from AI experimentation to measurable business outcomes up to 24x faster1 than custom-built implementations. Now available through the Lenovo AI Library, the added use cases provide proven starting points to accelerate AI deployments and realize returns from investments sooner. Alongside the expansion, new research conducted by The Futurum Group and Signal65 validates how Lenovo’s AI Library, infrastructure and services can help enterprises optimize AI economics fo
Follow-on Order Brings Orders from INNIO Data Center Customer to 1.72 GW, Further Strengthening INNIO’s Data Center Backlog and Revenue Visibility22.10.2026 14:30:00 CEST | Press release
Customer also signs long-term full maintenance agreement for first 500 MW, expanding INNIO’s recurring services base. INNIO N.V. (Nasdaq: INIO) today announced a 620 megawatt (MW) follow-on order from a leading developer and operator of mega-scale data center campuses in the U.S. Together with the customer’s 1.1 gigawatt (GW) order announced in July 2026, the new order brings cumulative orders from the customer to approximately 1.72 GW, further strengthening INNIO’s order backlog and visibility into future revenues. “This follow-on order, coming just months after the customer’s initial 1.1 GW order, underscores the strength of customer demand and continued confidence in INNIO. Our containerized Jenbacher solutions deliver what data centers need most: fast deployment, high power density, fuel efficiency, and the performance to support demanding AI workloads,” said Dr. Olaf Berlien, President and CEO of INNIO. “Repeat orders of this scale, combined with long-term service agreements, stre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom